HKU Scholars Hub: Browsing DSpace

Browsing by Author Cescon, DW

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 5 of 5

	Title	Author(s)	Issue Date
	A phase 1b trial of AMG386 and temsirolimus in patients with advanced solid tumor Proceeding/Conference:26th EORTC-NCI-AACR Symposium	Chiu, WYJ Hotte, SJ Kollmannsberger, CK Renouf, DJ Cescon, DW Hedley, D Chow, S Moscow, J Perry, M Diaz-Padilla, I Tan, D Hirte, H McWhirter, E Chen, H Siu, LL Bedard, PL	2014
	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041) Journal:Investigational New Drugs	Chiu, WYJ Hotte, SJ Kollmannsberger, CK Renouf, DJ Cescon, DW Hedley, D Chow, S Moscow, J Perry, M Diaz-Padilla, I Tan, D Hirte, H McWhirter, E Chen, H Siu, LL Bedard, PL	2016
	Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression Journal:Cancer Cell	Harris, IS Treloar, AE Inoue, S Sasaki, M Gorrini, C Lee, KC Yung, KY Brenner, D Knobbe-Thomsen, CB Cox, MA Elia, A Berger, T Cescon, DW Adeoye, A Brüstle, A Molyneux, SD Mason, JM Li, WY Yamamoto, K Wakeham, A Berman, HK Khokha, R Done, SJ Kavanagh, TJ Lam, CW Mak, TW	2015
	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Journal:The Lancet	Cortes, J Cescon, DW Rugo, HS Nowexcki, Z Im, SA Kwong, A Karantza, V Schmid, P	2020
	Polo‐like kinase 4 inhibitor CFI‐400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity Journal:Hepatology	Chan, YK YUEN, WH Chiu, KC Goh, CC Thu, KL Cescon, DW Soria‐Bretones, I Law, CT CHEU, WS Lee, D Tse, PW Tan, KV Zhang, S WONG, PY Wong, CM Khong, PL Ng, IOL Bray, MR Mak, TW Yau, TCC Wong, CCL	2022

Showing results 1 to 5 of 5